Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis Intervention:   Drug: Rituximab Sponsors:   Universitaire Ziekenhuizen KU Leuven;   Fonds voor Wetenschappelijk Reumaonderzoek (FWRO) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials